Innovations

# Clinical Risk Factors Associated with Peripartum Maternal Bacteremia: A Comprehensive Review

**Dr Juhi Godara[1], Dr Hamdah Meer[2], Dr Fazeela Ansari[3], Dr Sudheer Pratap Godara[4]**

[1]Specialist obstetrics and gynecology, Dubai hospital, Dubai, [2]Year 5 student, Dubai medical college, Dubai, [3]Year 5 student, Dubai medical college, Dubai, [4]Specialist Anaesthesiology, Rashid Hospital, Dubai.

Corresponding Author: **Dr Juhi Godara**

***Abstract:*** *Peripartum maternal bacteremia is a serious condition with significant consequences for maternal and neonatal health. This review aims to elucidate the clinical risk factors associated with peripartum bacteremia by integrating demographic, obstetric, medical, and molecular data. The peripartum period, encompassing late pregnancy to the early postpartum weeks, involves substantial physiological changes that increase susceptibility to infections. Key risk factors include maternal age, socioeconomic status, obstetric history, pre-existing medical conditions, and pregnancy-associated factors like preterm labor and prolonged rupture of membranes. The mode of delivery, particularly emergency cesarean sections, further influences bacteremia risk. Postpartum hemorrhage and surgical site infections also contribute to this condition. At the molecular level, the interplay between host immune responses and bacterial virulence factors such as those from Group B Streptococcus, Escherichia coli, and Staphylococcus aureus is critical. Understanding these factors is essential for developing targeted prevention, diagnosis, and treatment strategies to improve maternal and neonatal outcomes. This comprehensive synthesis provides valuable insights for clinicians and researchers, guiding future research directions and enhancing clinical practices to address this significant public health challenge.*

***Keywords:*** *Postpartum, Bacterimia, S. Aureus, E coli, TLR*

## Introduction :

Peripartum maternal bacteremia is a perilous condition with enormous implications for maternal and neonatal well-being. Defined as the presence of bacteria in the bloodstream throughout the peripartum phase, leading to severe headaches, sepsis, endometritis, and maternal mortality[1]. The peripartum period, encompassing the final trimester of pregnancy through the first few weeks postpartum, is a time of widespread physiological modifications, rendering females vulnerable to infections[2]. The purpose of this review is to explain the clinical risk elements related to peripartum

maternal bacteremia, integrating demographic, obstetric, scientific, and molecular statistics to provide a complete overview of this formidable condition.

Bacteremia can originate from a couple of sources, at some point peripartum from multiple sources like the genital, urinary, and gastrointestinal tracts[3]. During pregnancy, the immune system undergoes widespread modifications to aid in fetal development, which ironically increases susceptibility to infections[3]. This immunological shift includes stability between pro-inflammatory and anti-inflammatory states to protect both the mother and the fetus whilst averting immune-mediated fetal harm[4]. However, these adjustments can also predispose pregnant women to bacterial infections that ascend from the lower genital tract or are introduced during obstetric management[4].

Demographic factors greatly influence the risk of occurrence of peripartum bacteremia. Maternal age is a critical determinant, with very young and older mothers having higher susceptibility[5]. Young mothers frequently lack adequate prenatal care and health education, whereas older moms often have pre-existing conditions that elevate the risk of getting infected[5]. Socioeconomic status is another influential element. Women from lower socioeconomic backgrounds frequently face limitations in getting access to exceptional healthcare, resulting in delayed or inadequate remedies for infections[6]. Furthermore, certain ethnic groups show higher rates of occurrence of peripartum bacteremia, doubtlessly due to genetic predispositions, cultural practices, or disparities in access to healthcare or inadequate treatment[6].

Obstetric records, such as parity and former infections, are crucial in assessing the chance of peripartum bacteremia. Multiparous women, specifically those with short inter-pregnancy intervals, can also have an extended risk due to repeated exposure to healthcare environments and potential cumulative damage to the reproductive tract[7]. A history of urinary tract infections, sexually transmitted infections, or pelvic inflammatory disease can compromise the integrity of the genitourinary tract, facilitating bacterial entry into the bloodstream[8].

Medical conditions like diabetes mellitus, hypertension, and obesity are well-documented risk factors for peripartum infections. Diabetes, characterized by hyperglycemia and impaired immune response, provides a conducive environment for bacterial growth and dissemination[9]. Hypertension and preeclampsia, related to endothelial dysfunction and compromised immune defenses, further heighten the risk[10]. Obesity, connected to chronic irritation and impaired immune response, is another great risk aspect[11]. Conditions like these not only predispose ladies to infections but also complicate the medical management of bacteremia.

Pregnancy-associated factors, such as preterm labor and prolonged rupture of membranes (PROM), are closely linked to the occurrence of bacteremia. Preterm labor, described as labors occurring earlier than 37 weeks of gestation, is often associated with intra-amniotic infections that may cause bacteremia. PROM, characterized by the rupture of fetal membranes earlier than the onset of labor, creates a pathway for bacteria to ascend from the vagina into the otherwise sterile uterine surroundings, drastically elevating the risk of infection[12].

The mode of delivery is another critical element in the development of peripartum bacteremia. Cesarean section, especially when achieved emergently, is

related to a higher risk of bacteremia compared to vaginal delivery. The surgical operation, combined with the potential for extended labor and elevated manipulation, helps bacterial access into the bloodstream[13]. Furthermore, the use of intrapartum antibiotics, intended to prevent infections, can sometimes result in the emergence of antibiotic-resistant strains, further complicating the clinical course[14].

Postpartum elements, including postpartum hemorrhage and infections occurring at the surgical site, additionally contribute to the risk of bacteremia[15]. Postpartum hemorrhage, a leading cause of maternal morbidity and mortality, frequently necessitates invasive interventions that can introduce microorganisms into the bloodstream. Surgical site infections, especially following cesarean sections, are common causes of postpartum bacteremia[16]. Breastfeeding practices, while generally beneficial, can sometimes cause mastitis and subsequent bacteremia if managed inaccurately[17].

At the molecular level, the pathophysiology of peripartum bacteremia involves complex interactions between host immunity and bacterial pathogens. Common pathogens include Gram-positive microorganisms such as Group B Streptococcus (GBS) and Staphylococcus aureus, and Gram-negative bacteria like Escherichia coli[18]. These microorganisms possess virulence factors allowing them to evade the host immune response and establish infections. For example, GBS expresses surface proteins that facilitate adherence to epithelial cells and tissue invasion. E. coli, especially uropathogenic strains, produces bacterial toxins and enzymes that disrupt cell barriers and facilitate bacterial dissemination[19].

The host immune response to bacterial invasion involves both innate and adaptive mechanisms. Toll-like receptors (TLRs) on immune cells recognize pathogen-associated molecular patterns (PAMPs), triggering inflammatory responses aimed at eliminating the microorganisms[20]. However, excessive inflammation can lead to tissue damage and systemic manifestations of sepsis. Understanding these molecular interactions is essential for developing targeted treatment options and preventive strategies to mitigate the risk of peripartum bacteremia.

In conclusion, peripartum maternal bacteremia is a multifactorial condition influenced by demographic, obstetric, pathological, and molecular factors. By comprehensively analyzing these risk factors, this review aims to provide valuable insights for clinicians and researchers to enhance the prevention, diagnosis, and management of peripartum bacteremia, ultimately improving maternal and neonatal outcomes. This synthesis of current knowledge will aid in identifying at-risk populations, refining clinical practices, and guiding new research directions to address this significant public health challenge.

**Methods :**

Literature Review Approach:

A complete review of literaturewas carried out using databases consisting of PubMed, Scopus, and Google Scholar. Keywords like "peripartum bacteremia," "maternal bacteremia risk elements," and associated phrases had been used to discover applicable studies posted between 2000 and 2023. Inclusion standards encompassed studies that specialized in clinical risk factors associated with peripartum

maternal bacteremia. Articles had been screened based on their relevance to demographic factors, obstetric facts, clinical situations, and molecular pathophysiology. A general of 78 studies were selected for detailed review, comprising peer-reviewed articles, systematic reviews, and meta-analyses. Data extraction and synthesis had been guided by using thematic analysis to consolidate findings across numerous study designs.

**Discussion :**

Peripartum bacteremia is characterised by way of complicated interactions between bacterial pathogens and the host immune system, orchestrated with the aid of intricate molecular mechanisms. GBS, a leading purpose of maternal infections, deploys surface adhesins together with pilus proteins and lipoteichoic acids to stick to and invade host epithelial cells[21].

GBS, a β-hemolytic, gram-positive bacterium, can asymptomatically colonize the lower genital and gastrointestinal tracts of pregnant women, causing serious infections such as peripartum maternal bacteremia. Rarely, GBS can cause maternal sepsis, especially around the time of delivery. GBS's colonization rate is about 18% globally, with significant regional variations. Molecularly, GBS's virulence is due to its ability to bind host surfaces and evade immune defenses, encouraged by specific virulence factors that enhance its dissemination and infection causing capacity. The transition from a colonizer to an invasive pathogen in pregnant women can lead to several clinical outcomes, including sepsis, which requires prompt medical intervention.

Despite the use of intrapartum antibiotic prophylaxis (IAP) to prevent neonatal GBS infections, the global burden of maternal GBS disease remains a concern, particularly due to rising antibiotic resistance. Understanding the molecular mechanisms of GBS and the host factors that influence its pathogenicity is essential for developing better preventive and therapeutic strategies.Once set up, GBS secretes hemolysins, hyaluronidase, and immunomodulatory toxins such as beta-hemolysin/cytolysin, which further contributes to tissue harm and evades immune detection[22].

E. Coli, particularly uropathogenic strains, harness several virulence factors thatcolonizes the urinary tract and sometimes ascend to the kidneys, causing severe infections which include bacteremia. Key pathogens involved in peripartum bacteremia include Uropathogenic Escherichia coli (UPEC), which utilize numerous virulence factors such as pili, curli, flagella, and secreted toxins to colonize and invade the host. UPEC's ability to form biofilms and Intracellular Bacterial Communities (IBCs) in the bladder epithelium facilitates persistent infections and evasion of host immune responses.

The bladder epithelium itself employs several defense mechanisms, including the secretion of antimicrobial substances and the physical barrier of umbrella cells. However, UPEC can overcome these defenses through mechanisms such as the secretion of α-hemolysin and the formation of outer-membrane vesicles that protect and deliver virulence factors. Additionally, iron acquisition systems, including siderophores and TonB-dependent receptors, play a crucial role in UPEC survival in the iron-limited urinary tract environment. The host immune response involves the

recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by pattern recognition receptors (PRRs), leading to the activation of inflammasomes and production of proinflammatory cytokines[23].

GBS, a leading purpose of maternal infections, deploys surface adhesins together with pilus proteins and lipoteichoic acids to stick to and invade host epithelial cells[21]. These virulence factors facilitate bacterial colonization of the genital tract and subsequent dissemination to the bloodstream, causing bacteremia. Once set up, GBS secretes hemolysins, hyaluronidase, and immunomodulatory toxins such as beta-hemolysin/cytolysin, which further contributes to tissue harm and evades immune detection[22].

E. Coli, particularly uropathogenic strains, harness several virulence factors thatcolonizes the urinary tract and sometimes ascend to the kidneys, causing severe infections which include bacteremia. Key virulence determinants include Type 1 and P fimbriae, which mediate adhesion to uroepithelial cells, and toxins which includes hemolysin and cytotoxic necrotizing factor, which disrupts cell membrane of the host and facilitate bacterial dissemination[23,24]. Moreover, LPS, a major aspect of the outer membrane of Gram-negative bacteria like E. Coli, triggers robust inflammatory responses through TLR4 activation, main to the production of pro-inflammatory cytokines and systemic inflammation[25].

S. aureus is a formidable pathogen responsible for various infections, including peripartum bacteria. Its virulence is driven by numerous factors, including surface proteins that facilitate adhesion to host tissues, immune evasion mechanisms, and secreted toxins that damage host cells. The pathogen's ability to form biofilms further enhances its persistence and resistance to antibiotics, complicating treatment efforts.

S. aureus produces a variety of secreted toxins and extracellular enzymes that contribute to its pathogenicity. Notable toxins include α-toxin, which forms pores in host cell membranes, and Panton-Valentine leukocidin (PVL), which specifically targets and lyses neutrophils. These toxins not only cause direct cell damage but also modulate the host immune response, facilitating bacterial spread and survival[27,28]

PVL is a significant virulence factor in S. aureus, especially associated with severe infections. It exerts potent cytotoxic effects on human neutrophils, leading to cell lysis and the release of pro-inflammatory mediators. PVL-induced cell death involves characteristic changes in cell morphology and an oxidative burst, which contrasts with the rapid, morphology-independent lysis caused by phenol-soluble modulins (PSMs). These differences highlight the complex interplay between various S. aureus toxins in promoting infection and immune evasion[28].

Understanding the molecular mechanisms of S. aureus virulence is crucial for managing peripartum bacteremia. Targeting specific virulence factors, such as PVL and α-toxin, could offer new therapeutic approaches to mitigate infection severity and improve patient outcomes. Additionally, addressing the biofilm-forming ability of S. aureus may enhance the efficacy of existing antibiotics and reduce the incidence of persistent infections.

The host immunity plays a pivotal part in combating bacterial pathogens all through peripartum bacteremia. Innate immune mechanisms, along with pattern

recognizing receptors (PRRs) which include TLRs, recognize conserved microbial structures known as PAMPs[29,30].

Peripartum bacteremia has molecular mechanisms primarily mediated through TLRs, with TLR4 playing the chief role.TLRs, as pattern recognition receptors, identify pathogen-associated molecular patterns such as bacterial lipopolysaccharides. In TLR4, recognition of these components triggers a cascade of intracellular signaling. TLR4 activation recruits the adaptor protein MyD88, which further activates downstream pathways, notably NF-kB and MAPK. This signaling cascade leads to the transcription of genes responsible for producing pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β. These cytokines are crucial for initiating and sustaining the inflammatory response required to combat bacterial infections.

The inflammatory response mediated by TLR4 is vital for managing peripartum bacteremia, as it helps control the infection and limit its spread. However, alterations or dysregulation of TLR4 signaling can impact the effectiveness of this response. Factors such as aging or immune system changes during pregnancy may influence TLR4 function, potentially affecting the severity and progression of bacteremia. Understanding these molecular pathways is essential for developing targeted therapeutic strategies to better manage bacterial infections and enhance maternal health during the peripartum period[29,30]. (Table 1)

| Aspect | Details |
|---|---|
| Key Receptor | Toll-like Receptor 4 (TLR4) |
| Pathogen Recognition | TLR4 detects pathogen-associated molecular patterns (PAMPs) such as bacterial lipopolysaccharides (LPS) |
| Adaptor Proteins | MyD88 (Myeloid differentiation primary response 88) |
| Downstream Pathways | NF-kB (Nuclear factor kappa-light-chain-enhancer of activated B cells), MAPK (Mitogen-Activated Protein Kinases) |
| Inflammatory Mediators | Pro-inflammatory cytokines: TNF-α (Tumor Necrosis Factor-alpha), IL-6 (Interleukin-6), IL-1β (Interleukin-1 beta) |
| Immune Response | Initiates and sustains an inflammatory response to combat bacterial infection |
| Potential Dysregulation | Alterations due to factors such as aging or changes during pregnancy may affect TLR4 function |
| Clinical Relevance | Understanding TLR4 signaling helps in managing peripartum bacteremia and improving maternal health |

Staphylococcus aureus, another common reason of postpartum infections, produces an array
of virulence producing elements together with protein A, which binds to the Fc site of immunoglobulins to elude opsonization and phagocytosis by way of immune cells[26]. Additionally, S. Aureus secretes exotoxins such as alpha-hemolysin and Panton-Valentine leukocidin (PVL), which disrupt cell membranes and result in cytotoxicity, contributing to tissue necrosis and systemic unfold[27,28].

The host immunity plays a pivotal part in combating bacterial pathogens all through peripartum bacteremia. Innate immune mechanisms, along with pattern recognizing receptors (PRRs) which include TLRs, recognize conserved microbial structures known as PAMPs[29,30]. Activation of TLR signaling pathways triggers downstream cascades that culminate within the production of inflammatory cytokines (e.G., TNF-α, IL-1β) and chemokines, recruiting neutrophils and macrophages to the site of contamination to phagocytose and remove invading microorganism.[31,32]

Complement activation, via classical, substitutional, and lectin pathways, adorns the opsonization of microorganism, facilitating their identification and elimination with the help of phagocytes. Components of the Complement also make a contribution to the formation of membrane attack complexes (MACs), which lyse bacterial membranes and immediately kills pathogens[33]. Dysregulation of complement activation can impair host protection mechanisms, predisposing people to recurrent or chronic infections.

Understanding the molecular dynamics of peripartum bacteremia is essential for optimizing the management strategies. Diagnostic techniques integrating molecular techniques such as polymerase chain response (PCR) for pathogen detection and next-generation sequencing for genomic evaluation enable fast identity of bacterial species and antimicrobial resistance profiles[34]. This helps well timed initiation of focused antibiotic remedy tailored to the unique pathogens recognized, thereby improving treatment consequences and decreasing the risk of complications[35].

Therapeutic techniques targeting bacterial virulence factors, which include monoclonal antibodies towards surface adhesins or toxins, constitute innovative approaches to enhance host immune responses and fight multidrug-resistant infections[36]. Adjunctive remedies, including immunomodulators or anti-inflammatory agents, might also mitigate excessive host inflammatory responses related to intense bacteremia and sepsis, potentially enhancing affected person survival and lowering long-term sequelae[37].

Future research endeavors should elucidate the genetic and environmental factors influencing susceptibility to peripartum bacteremia, which includes host genetic polymorphisms related to immune responses and bacterial pathogenicity. Exploring the function of the microbiome in modulating host immune defenses and susceptibility to infections could find novel curative targets for intervention. Furthermore, advancing vaccine development against high-risk bacterial pathogens implicated in peripartum infections, inclusive of GBS and resistant traces of E. Coli and S. Aureus, holds promise for preventing maternal and neonatal morbidity and mortality[38,39].

Despite advancements in understanding the molecular basis of peripartum bacteremia, several challenges remain. Variability in microbial virulence factors and host immune responses necessitates personalized approaches to diagnosis and treatment. The emergence of multidrug-resistant pathogens and the complexity of host-pathogen interactions underscore the need for continuous surveillance and adaptation of clinical practices to mitigate the impact of infectious diseases on maternal and neonatal health[40].

Investigations into antimicrobial stewardship techniques and the improvement of novel antimicrobial agents capable of focusing on multidrug-resistant bacteria are imperative to cope with the global mission of antibiotic resistance. Additionally, improving healthcare infrastructure and promoting equitable access to maternal healthcare services are crucial for lowering disparities in peripartum infection charges and improving results in underserved populations.

Despite improvements in information the molecular basis of peripartum bacteremia, several demanding situations remain. Variability in microbial virulence elements and host immune responses necessitates personalized procedures to prognosis and treatment. The emergence of multidrug-resistant pathogens and the complexity of host-pathogen interactions underscore the want for non-stop surveillance and variation of clinical practices to mitigate the impact of infectious illnesses on maternal and neonatal well-being.

**Conclusion:**

To conclude, peripartum maternal bacteremia represents a multifaceted clinical syndrome determined with the aid of complex molecular interactions between bacterial pathogens and host immune responses. Enhanced knowledge of these molecular mechanisms informs targeted diagnostic strategies, healing interventions, and preventive measures aimed at optimizing maternal and neonatal health effects.

Continued interdisciplinary studies efforts are essential to unraveling the complexities of peripartum bacteremia and translating findings into impactful medical practice. By integrating molecular insights with scientific knowledge, healthcare carriers can strengthen the management of peripartum infections, mitigate the weight of antimicrobial resistance, and enhance maternal and neonatal health globally.

***References:***

1. *Easter SR, Molina RL, Venkatesh KK, Kaimal A, Tuomala R, Riley LE. Clinical risk factors associated with peripartum maternal bacteremia. Obstetrics and Gynecology (New York 1953 Online)/Obstetrics and Gynecology [Internet]. 2017 Oct 1;130(4):710–7.*
2. *Boushra M, Rahman O. Postpartum Infection. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: www.ncbi.nlm.nih.gov*
3. *Madrazo M, López-Cruz I, Piles L, Artero S, Alberola J, Aguilera JA, et al. Risk factors for bacteremia and its clinical impact on complicated Community-Acquired Urinary Tract Infection. Microorganisms [Internet]. 2023 Aug 2;11(8):1995.*

4. *Mor G, Cardenas I. Review Article: The Immune System in Pregnancy: A Unique complexity. American Journal of Reproductive Immunology [Internet]. 2010 May 10;63(6):425–33.*
5. *Nam JY, Oh SS, Park EC. The Association between Adequate Prenatal care and severe maternal morbidity among teenage pregnancies: A Population-Based Cohort study. Frontiers in Public Health [Internet]. 2022 May 31;10.*
6. *Dahab R, Sakellariou D. Barriers to accessing maternal care in Low income countries in Africa: A systematic review. International Journal of Environmental Research and Public Health/International Journal of Environmental Research and Public Health [Internet]. 2020 Jun 16;17(12):4292.*
7. *Dasa TT, Okunlola MA, Dessie Y. Effect of grand multiparity on adverse maternal outcomes: A prospective cohort study. Frontiers in Public Health [Internet]. 2022 Oct 13;10.*
8. *Attali E, Kern G, Warshaviak M, Reicher L, Many A, Yogev Y, et al. Intrapartum fever complicated with maternal bacteremia: prevalence, bacteriology, and risk factors. Archives of Gynecology and Obstetrics [Internet]. 2024 May 26;310(1):195–202.*
9. *Yefet E, Bejerano A, Iskander R, Kimhi TZ, Nachum Z. The Association between Gestational Diabetes Mellitus and Infections in Pregnancy—Systematic Review and Meta-Analysis. Microorganisms [Internet]. 2023 Jul 31;11(8):1956.*
10. *Harrison RK, Egede LE, Palatnik A. Peripartum infectious morbidity in women with preeclampsia. Journal of Maternal-fetal and Neonatal Medicine/Journal of Maternal-fetal & Neonatal Medicine [Internet]. 2019 Jun 19;34(8):1215–20.*
11. *Gutvirtz G, Wainstock T, Landau D, Sheiner E. Maternal obesity and offspring Long-Term infectious morbidity. Journal of Clinical Medicine [Internet]. 2019 Sep 14;8(9):1466.*
12. *Mu Y, Hu A, Kan H, Li Y, He Y, Fan W, et al. Preterm Prelabor Rupture of Membranes Linked to Vaginal Bacteriome of Pregnant Females in the Early Second Trimester: a Case-Cohort Design. Reproductive Sciences [Internet]. 2023 Feb 1;30(7):2324–35.*
13. *Kankuri E, Kurki T, Carlson P, Hiilesmaa V. Incidence, treatment and outcome of peripartum sepsis. Acta Obstetricia Et Gynecologica Scandinavica [Internet]. 2003 Jul 9;82(8):730–5.*
14. *Wilkie GL, Prabhu M, Ona S, Easter SR, Tuomala RE, Riley LE, et al. Microbiology and antibiotic resistance in peripartum bacteremia. Obstetrics and Gynecology (New York 1953 Online)/Obstetrics and Gynecology [Internet]. 2019 Feb 1;133(2):269–75.*
15. *Olutoye AS, Agboola AD, Bello OO. Puerperal Sepsis At University College Hospital, Ibadan: A 10-Year Review. Ann Ib Postgrad Med. 2022 Jun;20(1):32-39. PMID: 37006644; PMCID: PMC10061674.*
16. *Kawakita T, Landy HJ. Surgical site infections after cesarean delivery: epidemiology, prevention and treatment. Maternal Health, Neonatology and Perinatology [Internet]. 2017 Jul 5;3(1).*
17. *Blackmon MM, Nguyen H, Mukherji P. Acute Mastitis. [Updated 2023 Jul 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: www.ncbi.nlm.nih.gov*
18. *Mohn SF, Reimer R, Mar N, Katelieva A, Paquette V, Albert AYK, et al. Empiric antibiotics for peripartum bacteremia: A chart review from a quaternary Canadian*

*centre. International Journal of Gynaecology and Obstetrics [Internet]. 2023 Sep 1;164(2):786–92.*

19. *Surgers L, Bleibtreu A, Burdet C, Clermont O, Laouénan C, Lefort A, et al. Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses. Clinical Microbiology and Infection [Internet]. 2014 Dec 1;20(12):O1035–41.*
20. *Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-Like Receptor signaling and its role in Cell-Mediated Immunity. Frontiers in Immunology [Internet]. 2022 Mar 3;13.*
21. *Armistead B, Oler E, Waldorf KA, Rajagopal L. The double life of group B streptococcus: asymptomatic colonizer and potent pathogen. Journal of Molecular Biology/Journal of Molecular Biology [Internet]. 2019 Jul 1;431(16):2914–31.*
22. *Liu Y, Liu J. Group B Streptococcus: virulence factors and pathogenic mechanism. Microorganisms [Internet]. 2022 Dec 15;10(12):2483.*
23. *Zagaglia C, Ammendolia MG, Maurizi L, Nicoletti M, Longhi C. Urinary Tract Infections Caused by Uropathogenic Escherichia coli Strains—New Strategies for an Old Pathogen. Microorganisms [Internet]. 2022 Jul 14;10(7):1425.*
24. *Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies. Frontiers in Microbiology [Internet]. 2017 Aug 15;8.*
25. *Mazgaeen L, Gurung P. Recent advances in lipopolysaccharide recognition systems. International Journal of Molecular Sciences [Internet]. 2020 Jan 7;21(2):379.*
26. *Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence [Internet]. 2021 Jan 31;12(1):547–69.*
27. *Tam K, Torres VJ. Staphylococcus aureusSecreted Toxins and Extracellular Enzymes. Microbiology Spectrum [Internet]. 2019 Apr 12;7(2).*
28. *Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, et al. Staphylococcus aureus Panton-Valentine Leukocidin Is a Very Potent Cytotoxic Factor for Human Neutrophils. PLOS Pathogens [Internet]. 2010 Jan 8;6(1):e1000715.*
29. *Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-Like Receptor signaling and its role in Cell-Mediated Immunity. Frontiers in Immunology [Internet]. 2022 Mar 3;13.*
30. *El-Zayat SR, Sibaii H, Mannaa FA. Toll-like receptors activation, signaling, and targeting: an overview. Bulletin of the National Research Centre/Bulletin of the National Research Center [Internet]. 2019 Dec 1;43(1).*
31. *Kim HJ, Kim H, Lee JH, Hwangbo C. Toll-like receptor 4 (TLR4): new insight immune and aging. Immunity & Ageing [Internet]. 2023 Nov 24;20(1).*
32. *Kumar V, Stewart JH IV. Toll-like receptors in Immunity and inflammation. In: IntechOpen eBooks [Internet]. 2024.*
33. *Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-Like Receptor signaling and its role in Cell-Mediated Immunity. Frontiers in Immunology [Internet]. 2022 Mar 3;13.*
34. *Järvinen AK, Laakso S, Piiparinen P, Aittakorpi A, Lindfors M, Huopaniemi L, et al. Rapid identification of bacterial pathogens using a PCR- and microarray-based assay. BMC Microbiology [Internet]. 2009 Aug 10;9(1).*
35. *Dung TTN, Phat VV, Vinh C, Lan NPH, Phuong NLN, Ngan LTQ, et al. Development and validation of multiplex real-time PCR for simultaneous detection of six bacterial pathogens causing lower respiratory tract infections and antimicrobial resistance genes. BMC Infectious Diseases [Internet]. 2024 Feb 7;24(1).*

36. *Poritz MA, Lingenfelter B. Multiplex PCR for detection and identification of microbial pathogens. In: Springer eBooks [Internet]. 2018. p. 475–93.*
37. *Kumar V. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. International Immunopharmacology [Internet]. 2020 Dec 1;89:107087.*
38. *Staude B, Oehmke F, Lauer T, Behnke J, Göpel W, Schloter M, et al. The Microbiome and Preterm Birth: A Change in Paradigm with Profound Implications for Pathophysiologic Concepts and Novel Therapeutic Strategies. BioMed Research International [Internet]. 2018 Oct 2;2018:1–12.*
39. *Yu J, Pereira GMV, Allen-Brady K, Cuffolo R, Siddharth A, Koch M, et al. Genetic polymorphisms associated with UTI in children and adults: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology [Internet]. 2024 Jun 1;230(6):600-609.e3.*
40. *Vekemans J, Moorthy V, Friede M, Alderson MR, Meulen AST, Baker CJ, et al. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine [Internet]. 2019 Nov 1;37(50):7391–3.*